RxDoctor Payments Data

David Cox, MD

Infectious Disease · Greenwood, INNPI 1861474231

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,340 of the $1,593 with a category attached, or 84.1%. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.

$1,593in general payments, 2019–2025

Across 95 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$281
  • AbbVie$179
  • Gilead$148
  • Shionogi Inc$146
  • Paratek Pharmaceuticals, Inc.$139
  • Insmed, Inc.$138
  • plus $562 from 14 others

What the payments were for

  • Food & beverage$1,34084%
  • Education$25416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,593 in reported general payments places this provider in the 75th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$87,799
Medicare patients
257
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen40$155,847
Daptomycin16$61,241
IsentressRaltegravir Potassium24$47,813
DovatoDolutegravir Sodium/Lamivudine12$40,725
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df35$37,248
Lopinavir-RitonavirLopinavir/Ritonavir16$17,062
Rifampin67$5,662
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam25$5,204
Ethambutol Hcl55$4,640
CeftriaxoneCeftriaxone Sodium23$2,346
Cephalexin104$1,843
Doxycycline Hyclate38$1,561
Azithromycin62$1,304
Vancomycin Hcl13$1,165
Minocycline Hcl13$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya$148$155,84740 claims
MerckIsentress$281$47,81324 claims
Viiv Healthcare CompanyDovato$96$40,72512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →